BioCentury | Aug 10, 2009
Finance

Ebb & Flow

...On the year, Oncothyreon is up 583%, from $0.81 on Jan. 2. The company, formerly Biomira Inc....
BioCentury | May 19, 2008
Company News

Oncothyreon, Merck KGaA deal

...Oncothyreon (formerly Biomira Inc. ) received a $3 million milestone payment from Merck KGaA under a 2001...
BioCentury | Apr 7, 2008
Strategy

Takeda fills a gap

...to pay up to $150 million in license fees, milestone payments and equity investments to Biomira Inc....
BioCentury | Dec 24, 2007
Company News

Oncothyreon, Merck KGaA deal

...ONTY (formerly Biomira Inc. ) received a $5 million milestone payment from MRK under a 2001 deal...
BioCentury | Oct 29, 2007
Clinical News

PX-866: Phase I start

...Early next year, BIOM hopes to begin a Phase I trial. Biomira Inc. (TSX:BRA; BIOM), Edmonton, Alberta...
BioCentury | Sep 24, 2007
Company News

CG Therapeutics board of directors update

...CG Therapeutics Inc. , Seattle, Wash. Business: Cancer Appointed: Christopher Henney, chairman of Biomira Inc. and SGX...
BioCentury | Sep 10, 2007
Clinical News

Stimuvax: Updated Phase IIb data

...not significant (see BioCentury, April 5, 2004). MRK has worldwide rights to Stimuvax from BRA. Biomira Inc....
BioCentury | Sep 3, 2007
Clinical News

PX-478: Phase I started

...with standard therapy to evaluate oral PX-478 given on days 1-5 during a 21-day cycle. Biomira Inc....
BioCentury | Aug 13, 2007
Company News

Biomira, Merck KGaA deal

...include milestones related to manufacturing, scale-up and process development transfer. Further terms were not disclosed. Biomira Inc....
BioCentury | Jul 23, 2007
Company News

Biomira management update

Biomira Inc. (TSX:BRA; BIOM), Edmonton, Alberta Business: Cancer Hired: Gary Christianson as COO, formerly site director at GlaxoSmithKline plc 's biologics unit WIR Staff cancer...
Items per page:
1 - 10 of 260
BioCentury | Aug 10, 2009
Finance

Ebb & Flow

...On the year, Oncothyreon is up 583%, from $0.81 on Jan. 2. The company, formerly Biomira Inc....
BioCentury | May 19, 2008
Company News

Oncothyreon, Merck KGaA deal

...Oncothyreon (formerly Biomira Inc. ) received a $3 million milestone payment from Merck KGaA under a 2001...
BioCentury | Apr 7, 2008
Strategy

Takeda fills a gap

...to pay up to $150 million in license fees, milestone payments and equity investments to Biomira Inc....
BioCentury | Dec 24, 2007
Company News

Oncothyreon, Merck KGaA deal

...ONTY (formerly Biomira Inc. ) received a $5 million milestone payment from MRK under a 2001 deal...
BioCentury | Oct 29, 2007
Clinical News

PX-866: Phase I start

...Early next year, BIOM hopes to begin a Phase I trial. Biomira Inc. (TSX:BRA; BIOM), Edmonton, Alberta...
BioCentury | Sep 24, 2007
Company News

CG Therapeutics board of directors update

...CG Therapeutics Inc. , Seattle, Wash. Business: Cancer Appointed: Christopher Henney, chairman of Biomira Inc. and SGX...
BioCentury | Sep 10, 2007
Clinical News

Stimuvax: Updated Phase IIb data

...not significant (see BioCentury, April 5, 2004). MRK has worldwide rights to Stimuvax from BRA. Biomira Inc....
BioCentury | Sep 3, 2007
Clinical News

PX-478: Phase I started

...with standard therapy to evaluate oral PX-478 given on days 1-5 during a 21-day cycle. Biomira Inc....
BioCentury | Aug 13, 2007
Company News

Biomira, Merck KGaA deal

...include milestones related to manufacturing, scale-up and process development transfer. Further terms were not disclosed. Biomira Inc....
BioCentury | Jul 23, 2007
Company News

Biomira management update

Biomira Inc. (TSX:BRA; BIOM), Edmonton, Alberta Business: Cancer Hired: Gary Christianson as COO, formerly site director at GlaxoSmithKline plc 's biologics unit WIR Staff cancer...
Items per page:
1 - 10 of 260